| 0 | 💬 0 |
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.
(linkinghub.elsevier.com)
|
Lancet Infectious Diseases 2026-06-03 | #vaccination #clinical trial #rna #immunogenicity #safety |